Chemotherapy-Induced Takotsubo Syndrome

  • Monika Budnik
  • Jakub KucharzEmail author
  • Paweł Wiechno
  • Tomasz Demkow
  • Janusz Kochanowski
  • Elżbieta Górska
  • Grzegorz Opolski
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1114)


Cardiovascular complications are a significant problem in systemically treated cancer patients. One such complication is Takotsubo cardiomyopathy, also known as Takotsubo syndrome. It is most frequently defined as a sudden and transient left or right ventricular systolic dysfunction; mimicking acute coronary syndrome, but without the associated changes in coronary arteries. Takotsubo syndrome is a relatively little known complication that appears in the course of oncological treatment, and its incidence has not yet been established. In this study, we reviewed Medline database according to case reports concerning takotsubo syndrome appearing after systemic treatment in oncological patients. We took into consideration all types of anticancer drugs. We reviewed the changes reported in the electrocardiography, echocardiography, and coronary angiography, and also the level of troponin, a marker of acute coronary syndrome elevation. In view of the increasing frequency of cardiac complications reported in patients receiving systemic oncological treatment, Takotsubo syndrome appears to be underdiagnosed. However, the syndrome may be linked to potentially fatal complications such as cardiogenic shock or cardiac arrest. Therefore, it seems essential to carry out appropriate diagnostic procedures for every patient experiencing clinical side effects of onco-pharmacotherapy. In patients with chest pain and dyspnea during or after treatment, Takotsubo syndrome should be considered, particularly that the syndrome requires a different therapy approach than that used in a coronary syndrome. Diagnostic procedures should include echocardiogram and the assessment of myocardial necrosis markers and natriuretic peptides.


Cancer Cardiomyopathy Cardiotoxicity Chemotherapy Coronary syndrome Takotsubo syndrome 


Conflicts of Interest

The authors declare no conflicts of interest in relation to this article.


  1. Basselin C, Fontanges T, Descotes J, Chevalier P, Bui-Xuan B, Feinard G, Timour Q (2011) 5–Fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy 31:226CrossRefPubMedGoogle Scholar
  2. Baumann S, Huseynov A, Goranova D, Faust M, Behnes M, Nolte F, Heidenreich D, Hofmann WK, Borggrefe M, Akin I, Klein S (2014) Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncol Res Treat 37:487–490CrossRefPubMedGoogle Scholar
  3. Brunetti ND, Santoro F, De Gennaro L, Correale M, Gaglione A, Di Biase M (2016) Drug treatment rates with beta-blockers and ACE-inhibitors/angiotensin receptor blockers and recurrences in takotsubo cardiomyopathy: a meta-regression analysis. Int J Cardiol 214:340–342CrossRefPubMedGoogle Scholar
  4. Budnik M, Piatkowski R, Kochanowski J, Glowczynska R, Gorko D, Kowalik R, Pietrasik A, Opolski G (2015) The oldest patient with takotsubo cardiomyopathy. J Geriatr Cardiol 12:588–589PubMedPubMedCentralGoogle Scholar
  5. Budnik M, Kochanowski J, Piatkowski R, Wojtera K, Peller M, Gaska M, Glowacka P, Karolczak P, Ochijewicz D, Opolski G (2016) Simple markers can distinguish Takotsubo cardiomyopathy from ST segment elevation myocardial infarction. Int J Cardiol 219:417–420CrossRefPubMedGoogle Scholar
  6. Burgy M, Brossat H, Barthelemy P, Imperiale A, Trinh A, Hazam CA, Bergerat JP, Mathelin C (2014) First report of trastuzumab treatment after postoperative takotsubo cardiomyopathy. Anticancer Res 34:3579–3582PubMedGoogle Scholar
  7. Bybee KA, Kara T, Prasad A, Lerman A, Barsness GW, Wright RS, Rihal CS (2004) Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med 141:858–865CrossRefPubMedGoogle Scholar
  8. Coli S, Pigazzani F, Gaibazzi N (2015) Midventricular takotsubo cardiomyopathy after oxaliplatin infusion: an unreported side effect. J Cardiovasc Med 16:646–649CrossRefGoogle Scholar
  9. Damodaran S, Mrozek E, Liebner D, Kendra K (2014) Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma. J Natl Compr Cancer Netw 12(12):1666–1670CrossRefGoogle Scholar
  10. Drímal J, Zúrová-Nedelcevová J, Knezl V, Sotníková R, Navarová J (2006) Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab. Neuro Endocrinol Lett 27(Suppl 2):176–179PubMedGoogle Scholar
  11. Finsterer J, Stöllberger C, Pulgram T (2015) Paraneoplastic takotsubo syndrome with ventricular thrombus and stroke. Herz 40:632–634CrossRefPubMedGoogle Scholar
  12. Franco TH, Khan A, Joshi V, Thomas B (2008) Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 4:1367–1370CrossRefPubMedPubMedCentralGoogle Scholar
  13. Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E (2006) Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J 27:1523–1529CrossRefPubMedGoogle Scholar
  14. Goel S, Sharma A, Garg A, Chandra A, Shetty V (2014) Chemotherapy induced takotsubo cardiomyopathy. World J Clin Cases 2:565–568CrossRefPubMedPubMedCentralGoogle Scholar
  15. Grunwald MR, Howie L, Diaz LA (2012) Takotsubo cardiomyopathy and fluorouracil: case report and review of the literature. J Clin Oncol 30:e11–e14CrossRefPubMedGoogle Scholar
  16. Khakoo AY, Halushka MK, Rame JE, Rodriguez ER, Kasper EK, Judge DP (2005) Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med 2:53–57CrossRefPubMedGoogle Scholar
  17. Khanji M, Nolan S, Gwynne S, Pudney D, Ionescu A (2013) Tako-Tsubo syndrome after trastuzumab – an unusual complication of chemotherapy for breast cancer. Clin Oncol (R Coll Radiol) 25:329CrossRefGoogle Scholar
  18. Kim L, Karas M, Wong SC (2008) Chemotherapy-induced takotsubo cardiomyopathy. J Invasive Cardiol 20:338–340Google Scholar
  19. Klag T, Cantara G, Ong P, Kaufmann M, Sechtem U, Athanasiadis A (2014) Epicardial coronary artery spasm as cause of capecitabine-induced takotsubo cardiomyopathy. Clin Res Cardiol 103:247–250CrossRefPubMedPubMedCentralGoogle Scholar
  20. Knott K, Starling N, Rasheed S, Foran J, Cafferkey C, Rosen S, Nicholson A, Baksi J, Lyon A (2014) A case of Takotsubo syndrome following 5-fluorouracil chemotherapy. Int J Cardiol 177:e65–e67CrossRefPubMedGoogle Scholar
  21. Kobayashi N, Hata N, Yokoyama S, Shinada T, Shirakabe A, Mizuno K (2009) A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. J Nippon Med Sch 76:27–33CrossRefPubMedGoogle Scholar
  22. Lim SH, Wilson SM, Hunter A, Hill J, Beale P (2013) Takotsubo cardiomyopathy and 5-fluorouracil: getting to the heart of the matter. Case Rep Oncol Med 2013:206765PubMedPubMedCentralGoogle Scholar
  23. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G, Mebazaa A, Omerovic E (2016) Current state of knowledge on takotsubo syndrome: a position statement from the taskforce on Takotsubo syndrome of the heart failure Association of the European Society of Cardiology. Eur J Heart Fail 18:8–27CrossRefPubMedGoogle Scholar
  24. Malley T, Watson E (2016) A case of takotsubo cardiomyopathy after chemotherapy. Oxf Med Case Rep 2016:55–58CrossRefGoogle Scholar
  25. Napora M, Ganowicz E, Gorska R (2013) Correlation between the state of periodontal tissues and selected cardiovascular parameters in patients with type 2 diabetes. Centr Eur J Immunol 38(4):556–561CrossRefGoogle Scholar
  26. Ng KH, Dearden C, Gruber P (2015) Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? BMJ Case Rep 2015:bcr2014208203. CrossRefPubMedPubMedCentralGoogle Scholar
  27. Opolski G, Budnik M, Kochanowski J, Kowalik R, Piatkowski R, Kochman J (2016) Four episodes of takotsubo cardiomyopathy in one patient. Int J Cardiol 203:53–54CrossRefPubMedGoogle Scholar
  28. Ovadia D, Esquenazi Y, Bucay M, Bachier CR (2015) Association between takotsubo cardiomyopathy and axitinib: case report and review of the literature. J Clin Oncol 33(1):e1–e3CrossRefPubMedGoogle Scholar
  29. Ozturk MA, Ozveren O, Cinar V, Erdik B, Oyan B (2013) Takotsubo syndrome: an underdiagnosed complication of 5–fluorouracil mimicking acute myocardial infarction. Blood Coagul Fibrinolysis 24:90–94CrossRefPubMedGoogle Scholar
  30. Qasem A, Bin Abdulhak AA, Aly A, Moormeier J (2016) Capecitabine-induced takotsubo cardiomyopathy: a case report and literature review. Am J Ther 23(5):e1188–e1192CrossRefPubMedGoogle Scholar
  31. Saif MW, Shah MM, Shah AR (2009) Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 8:191–202CrossRefPubMedGoogle Scholar
  32. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232–1239CrossRefPubMedGoogle Scholar
  33. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F; ESMO Guidelines Committee (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 26(suppl 5):v8–v30CrossRefPubMedGoogle Scholar
  34. Singh SB, Harle IA (2014) Takotsubo cardiomyopathy secondary in part to cancer-related pain crisis: a case report. J Pain Symptom Manag 48:137–142CrossRefGoogle Scholar
  35. Sorrentino MF, Kim J, Foderaro AE, Truesdell AG (2012) 5-Fluorouracil induced cardiotoxicity: review of the literature. Cardiol J 19:453–458CrossRefPubMedGoogle Scholar
  36. Stewart T, Pavlakis N, Ward M (2010) Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 40:303–307CrossRefPubMedGoogle Scholar
  37. Sundaravel S, Alrifai A, Kabach M, Ghumman W (2017) FOLFOX induced takotsubo cardiomyopathy treated with impella assist device. Case Rep Cardiol 2017:8507096PubMedPubMedCentralGoogle Scholar
  38. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL et al (2015) Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med 373:929–938CrossRefGoogle Scholar
  39. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–2247CrossRefPubMedGoogle Scholar
  40. Y-Hassan S, Tornvall P, Törnerud M, Henareh L (2013) Capecitabine caused cardiogenic shock through induction of global Takotsubo syndrome. Cardiovasc Revasc Med 14(1):57–61CrossRefPubMedGoogle Scholar
  41. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Monika Budnik
    • 1
  • Jakub Kucharz
    • 2
    Email author
  • Paweł Wiechno
    • 2
  • Tomasz Demkow
    • 2
  • Janusz Kochanowski
    • 1
  • Elżbieta Górska
    • 3
  • Grzegorz Opolski
    • 1
  1. 1.First Department of CardiologyWarsaw Medical UniversityWarsawPoland
  2. 2.Department of Uro–OncologyMaria Sklodowska-Curie Memorial Cancer Center and Institute of OncologyWarsawPoland
  3. 3.Department of Laboratory Diagnostics and Clinical and Clinical Immunology of Developmental AgeWarsaw Medical UniversityWarsawPoland

Personalised recommendations